Oncolytics Biotech, Inc.

Twitter LinkedIn
  • Home
  • About
    • Our Company
    • Management Team
    • Board of Directors
  • Technology
    • What is Pelareorep?
    • What Does Pelareorep Do?
    • Delivery
    • Intellectual Property
    • Posters & Publications
    • Manufacturing
  • Clinical Trials
    • Clinical Development Plan
    • Collaborators
    • Pipeline
  • Media
    • Press Releases
    • Insights
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • FAQs
    • Email Alerts
    • IR Contacts
  • Contact
  • Careers

News

Media

Media

  • Press Releases
  • Insights
May 10, 2022

Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference

May 5, 2022

Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights

May 4, 2022

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

May 2, 2022

Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting

Apr 28, 2022

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Apr 21, 2022

Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor Conference

Apr 14, 2022

Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine

Apr 12, 2022

Oncolytics Biotech® to Participate in a Fireside Chat at the Canaccord Genuity Horizons in Oncology Virtual Conference

Apr 8, 2022

Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AACR Annual Meeting

Apr 8, 2022

Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...58
© 2022 Oncolytics Biotech, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap